The First Affiliated Hospital of HaErBin Medical University
Welcome,         Profile    Billing    Logout  
 11 Trials 
16 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lin, Rongbo
FNF-014, NCT03788226: A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer

Recruiting
3
600
RoW
POF, CAPOX/SOX/FOLFOX
Fujian Cancer Hospital
Gastric Cancer Stage III
12/21
12/23
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting
3
560
RoW
Irinotecan Hydrochloride Injection, HX008, Placebo
Taizhou Hanzhong biomedical co. LTD
Stomach Cancer
08/23
08/23
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
NCT04854668: A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Active, not recruiting
3
748
RoW
Anlotinib hydrochloride capsule, Bevacizumab, Oxaliplatin, Capecitabine
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Colorectal Cancer
12/24
12/25
NCT04734249: Second-line Surufatinib Combined With Chemotherapy in Advanced CRC

Not yet recruiting
2
56
NA
Surufatinib(HMPL-012), Chemotherapy(mFOLFOX6/FOLFIRI,FOLFOXIRI)
Fujian Cancer Hospital
Advanced Colorectal Cancer
03/21
12/23
NCT05839470: Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Recruiting
2
20
RoW
cadonilimab, irinotecan, Oxaliplatin, leucovorin or levoleucovorin, 5-FU
Fujian Cancer Hospital
Colorectal Cancer
03/24
03/25
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

Not yet recruiting
2
168
RoW
TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Chemotherapy
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Gastroesophageal Adenocarcinoma
09/26
09/27
NCT06166836: a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Recruiting
1/2
140
RoW
D1553, IN10018(Ifebemtinib), BI 853520
InxMed (Shanghai) Co., Ltd., InventisBio Co., Ltd
Solid Tumor
12/25
12/26
NCT04718402: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma

Terminated
1
21
RoW
Mitoxantrone Hydrochloride Liposome, intravenous injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Gastric Carcinoma
05/22
05/22
GQ1005-102, NCT06154343: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Recruiting
1
150
RoW
GQ1005
GeneQuantum Healthcare (Suzhou) Co., Ltd.
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
12/24
07/25
NCT05502393: A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

Recruiting
1
118
RoW
JS107, Toripalimab
Shanghai Junshi Bioscience Co., Ltd.
Advanced Solid Tumors
07/24
12/24
NCT05461768: A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

Recruiting
1
26
RoW
BL-M07D1
Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Breast Cancer, Locally Advanced or Metastatic Solid Tumor
06/25
12/25
NCT06839105: A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Not yet recruiting
1
214
RoW
Taxol, Cisplatin or Carboplatin, Pemetrexed, Oxaliplatin, Capecitabine, Bevacizumab, Renvastinib, AWT020
Shanghai Junshi Bioscience Co., Ltd.
Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
04/28
04/28
NCT06010901: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

Recruiting
1
75
RoW
TQB2618 injection, Penpulimab injection, Anlotinib hydrochloride capsules
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Colorectal Cancer
03/25
07/25
Chen, Gongyan
NCT04398940: A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer

Recruiting
2
71
RoW
TQ-B3139
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
01/22
10/22
NCT04237805 / 2013-001045-14: A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Recruiting
1/2
280
RoW
SAF-189s, foritinib succinate
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell
12/22
03/26
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lin, Rongbo
FNF-014, NCT03788226: A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer

Recruiting
3
600
RoW
POF, CAPOX/SOX/FOLFOX
Fujian Cancer Hospital
Gastric Cancer Stage III
12/21
12/23
NCT04486651: HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer

Recruiting
3
560
RoW
Irinotecan Hydrochloride Injection, HX008, Placebo
Taizhou Hanzhong biomedical co. LTD
Stomach Cancer
08/23
08/23
HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting
3
918
Europe, Canada, Japan, RoW
Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil
Jazz Pharmaceuticals, BeiGene
Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma
05/25
05/26
NCT04854668: A Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy as First-line Treatment in Subjects With RAS/BRAF Wild Metastatic Colorectal Cancer

Active, not recruiting
3
748
RoW
Anlotinib hydrochloride capsule, Bevacizumab, Oxaliplatin, Capecitabine
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Metastatic Colorectal Cancer
12/24
12/25
NCT04734249: Second-line Surufatinib Combined With Chemotherapy in Advanced CRC

Not yet recruiting
2
56
NA
Surufatinib(HMPL-012), Chemotherapy(mFOLFOX6/FOLFIRI,FOLFOXIRI)
Fujian Cancer Hospital
Advanced Colorectal Cancer
03/21
12/23
NCT05839470: Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer

Recruiting
2
20
RoW
cadonilimab, irinotecan, Oxaliplatin, leucovorin or levoleucovorin, 5-FU
Fujian Cancer Hospital
Colorectal Cancer
03/24
03/25
TQB2102-II-04, NCT06767800: A Clinical Trial Evaluating TQB2102 for Injection in Combination With Behmosubaisumab/Payamprolizumab With or Without Chemotherapy in Unresectable Locally Advanced, Recurrent, or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastroesophageal Adenocarcinoma

Not yet recruiting
2
168
RoW
TQB2102 for injection+Benmelstobart, TQB2102 for injection+Benmelstobart+Chemotherapy
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Gastroesophageal Adenocarcinoma
09/26
09/27
NCT06166836: a Study to Evaluate the Safety and Efficacy of D-1553 Combined With IN10018 in KRAS G12C Mutant Solid Tumors

Recruiting
1/2
140
RoW
D1553, IN10018(Ifebemtinib), BI 853520
InxMed (Shanghai) Co., Ltd., InventisBio Co., Ltd
Solid Tumor
12/25
12/26
NCT04718402: A Study of Mitoxantrone Hydrochloride Liposome Injection in the Treatment of Advanced Gastric Carcinoma

Terminated
1
21
RoW
Mitoxantrone Hydrochloride Liposome, intravenous injection
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced Gastric Carcinoma
05/22
05/22
GQ1005-102, NCT06154343: A Study of GQ1005 in Subjects With HER2-Expressing Advanced Solid Tumors

Recruiting
1
150
RoW
GQ1005
GeneQuantum Healthcare (Suzhou) Co., Ltd.
HER2 Expressing or Mutated Advanced Malignant Solid Tumors
12/24
07/25
NCT05502393: A Clinical Study to Evaluate the Safety and Tolerability of JS107 in Advanced or Metastatic Solid Tumors

Recruiting
1
118
RoW
JS107, Toripalimab
Shanghai Junshi Bioscience Co., Ltd.
Advanced Solid Tumors
07/24
12/24
NCT05461768: A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

Recruiting
1
26
RoW
BL-M07D1
Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc., Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Breast Cancer, Locally Advanced or Metastatic Solid Tumor
06/25
12/25
NCT06839105: A Clinical Study to Evaluate the Safety and Tolerability of AWT020 in Patients With Advanced Malignancies

Not yet recruiting
1
214
RoW
Taxol, Cisplatin or Carboplatin, Pemetrexed, Oxaliplatin, Capecitabine, Bevacizumab, Renvastinib, AWT020
Shanghai Junshi Bioscience Co., Ltd.
Non-Small Cell Lung Cancer, Colorectal Cancer, Renal Cell Carcinoma, Melanoma and Other Solid Tumor
04/28
04/28
NCT06010901: A Clinical Study of TQB2618 Injection Monotherapy and Combination Regimen (With Penpulimab Injection ±Anlotinib Hydrochloride Capsules) in the Four or Later Lines of Treatment of Advanced Colorectal Cancer.

Recruiting
1
75
RoW
TQB2618 injection, Penpulimab injection, Anlotinib hydrochloride capsules
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Colorectal Cancer
03/25
07/25
Chen, Gongyan
NCT04398940: A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer

Recruiting
2
71
RoW
TQ-B3139
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Non Small Cell Lung Cancer
01/22
10/22
NCT04237805 / 2013-001045-14: A Phase I/II Clinical Study of SAF-189s in Non-small Cell Lung Cancer (NSCLC) Patients

Recruiting
1/2
280
RoW
SAF-189s, foritinib succinate
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell
12/22
03/26

Download Options